Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
People with MASLD/MASH had similar semaglutide-mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.
Authors
- Mads Sundby Palle (ORCID: https://orcid.org/0009-0000-7127-2861)
- Mohamed Tawfik (ORCID: https://orcid.org/0000-0003-2382-2077)
- Matthew J. Armstrong (ORCID: https://orcid.org/0000-0002-3425-1161)
- Anne‐Sophie Sejling
- Michael Roden
- Takeshi Okanoue
Institutions
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Novo Nordisk (Denmark) (DK)
- National Institute for Health and Care Research (GB)
- Düsseldorf University Hospital (DE)
- Saiseikai Suita Hospital (JP)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Queen Elizabeth University Hospital (GB)
- German Center for Diabetes Research (DE)
- NIHR Birmingham Biomedical Research Centre (GB)
- Heinrich Heine University Düsseldorf (DE)
- University of Birmingham (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1111/dom.16065
- Citations
- 15
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.80
Funders
- Novo Nordisk